Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and ...

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

Omega Therapeutics is halting work on its only clinical-stage candidate as part of a strategic refocus centered on three ...

YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in Q3– TransCon CNP ...

This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...

In its third-quarter 2024 earnings report, Ginkgo Bioworks highlighted significant achievements in its strategic realignment, including signing new deals with Novo Nordisk and Merck, and making ...

So far this year, Eli Lilly (NYSE: LLY) has been on an absolute tear and is swiftly becoming the world's most prolific ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

We are proud to have recently announced, approximately just six months after starting this program, achievement of the first milestone under our collaboration, having delivered AI De Novo antibody ...

Digital health companies faced high advertising costs and focused on returns on investments in the third quarter.

Novo’s American depositary receipts rose 2.4% to $109.77 in Monday trading, but are still down 15% over the past three months ...